177 related articles for article (PubMed ID: 37931288)
1. Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma.
Li Z; Zhuang X; Pan CH; Yan Y; Thummalapalli R; Hallin J; Torborg S; Singhal A; Chang JC; Manchado E; Dow LE; Yaeger R; Christensen JG; Lowe SW; Rudin CM; Joost S; Tammela T
Cancer Discov; 2024 Feb; 14(2):308-325. PubMed ID: 37931288
[TBL] [Abstract][Full Text] [Related]
2. Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma.
Li Z; Zhuang X; Pan CH; Yan Y; Thummalapalli R; Hallin J; Torborg S; Singhal A; Chang JC; Manchado E; Dow LE; Yaeger R; Christensen JG; Lowe SW; Rudin CM; Joost S; Tammela T
bioRxiv; 2023 Oct; ():. PubMed ID: 37808711
[TBL] [Abstract][Full Text] [Related]
3. Alveolar type I cells can give rise to KRAS-induced lung adenocarcinoma.
Yang M; Shen H; Flodby P; Koss MD; Bassiouni R; Liu Y; Jashashvili T; Neely A; Ogbolu E; Castillo J; Stueve TR; Mullen DJ; Ryan AL; Carpten J; Castaldi A; Wallace WD; Zhou B; Borok Z; Marconett CN
Cell Rep; 2023 Dec; 42(12):113286. PubMed ID: 37995179
[TBL] [Abstract][Full Text] [Related]
4. An atlas of epithelial cell states and plasticity in lung adenocarcinoma.
Han G; Sinjab A; Rahal Z; Lynch AM; Treekitkarnmongkol W; Liu Y; Serrano AG; Feng J; Liang K; Khan K; Lu W; Hernandez SD; Liu Y; Cao X; Dai E; Pei G; Hu J; Abaya C; Gomez-Bolanos LI; Peng F; Chen M; Parra ER; Cascone T; Sepesi B; Moghaddam SJ; Scheet P; Negrao MV; Heymach JV; Li M; Dubinett SM; Stevenson CS; Spira AE; Fujimoto J; Solis LM; Wistuba II; Chen J; Wang L; Kadara H
Nature; 2024 Mar; 627(8004):656-663. PubMed ID: 38418883
[TBL] [Abstract][Full Text] [Related]
5. p53 governs an AT1 differentiation programme in lung cancer suppression.
Kaiser AM; Gatto A; Hanson KJ; Zhao RL; Raj N; Ozawa MG; Seoane JA; Bieging-Rolett KT; Wang M; Li I; Trope WL; Liou DZ; Shrager JB; Plevritis SK; Newman AM; Van Rechem C; Attardi LD
Nature; 2023 Jul; 619(7971):851-859. PubMed ID: 37468633
[TBL] [Abstract][Full Text] [Related]
6. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
[TBL] [Abstract][Full Text] [Related]
7. Inhibitor of Differentiation-1 Sustains Mutant
Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I
Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.
Nokin MJ; Darbo E; Travert C; Drogat B; Lacouture A; San José S; Cabrera N; Turcq B; Prouzet-Mauleon V; Falcone M; Villanueva A; Wang H; Herfs M; Mosteiro M; Jänne PA; Pujol JL; Maraver A; Barbacid M; Nadal E; Santamaría D; Ambrogio C
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32759499
[TBL] [Abstract][Full Text] [Related]
9. KRAS(G12D) drives lepidic adenocarcinoma through stem-cell reprogramming.
Juul NH; Yoon JK; Martinez MC; Rishi N; Kazadaeva YI; Morri M; Neff NF; Trope WL; Shrager JB; Sinha R; Desai TJ
Nature; 2023 Jul; 619(7971):860-867. PubMed ID: 37468622
[TBL] [Abstract][Full Text] [Related]
10.
Li F; Huang Q; Luster TA; Hu H; Zhang H; Ng WL; Khodadadi-Jamayran A; Wang W; Chen T; Deng J; Ranieri M; Fang Z; Pyon V; Dowling CM; Bagdatlioglu E; Almonte C; Labbe K; Silver H; Rabin AR; Jani K; Tsirigos A; Papagiannakopoulos T; Hammerman PS; Velcheti V; Freeman GJ; Qi J; Miller G; Wong KK
Cancer Discov; 2020 Feb; 10(2):270-287. PubMed ID: 31744829
[TBL] [Abstract][Full Text] [Related]
11. Loss of wild type KRAS in KRAS
Liu Y; Gao GF; Minna JD; Williams NS; Westover KD
Lung Cancer; 2021 Mar; 153():73-80. PubMed ID: 33465697
[TBL] [Abstract][Full Text] [Related]
12. FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling.
Morel M; Long W
Mol Oncol; 2024 Mar; 18(3):762-777. PubMed ID: 37983945
[TBL] [Abstract][Full Text] [Related]
13. RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS-mutated lung adenocarcinoma.
Li HS; Liu CM; Wang Y
Thorac Cancer; 2023 May; 14(15):1368-1382. PubMed ID: 37021520
[TBL] [Abstract][Full Text] [Related]
14. Modeling diverse genetic subtypes of lung adenocarcinoma with a next-generation alveolar type 2 organoid platform.
Naranjo S; Cabana CM; LaFave LM; Romero R; Shanahan SL; Bhutkar A; Westcott PMK; Schenkel JM; Ghosh A; Liao LZ; Del Priore I; Yang D; Jacks T
Genes Dev; 2022 Aug; 36(15-16):936-949. PubMed ID: 36175034
[TBL] [Abstract][Full Text] [Related]
15. HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis.
Jiang L; Wang R; Fang L; Ge X; Chen L; Zhou M; Zhou Y; Xiong W; Hu Y; Tang X; Li G; Li Z
Theranostics; 2019; 9(9):2460-2474. PubMed ID: 31131047
[No Abstract] [Full Text] [Related]
16. Tumor progression and chromatin landscape of lung cancer are regulated by the lineage factor GATA6.
Arnal-Estapé A; Cai WL; Albert AE; Zhao M; Stevens LE; López-Giráldez F; Patel KD; Tyagi S; Schmitt EM; Westbrook TF; Nguyen DX
Oncogene; 2020 Apr; 39(18):3726-3737. PubMed ID: 32157212
[TBL] [Abstract][Full Text] [Related]
17.
Wang X; Min S; Liu H; Wu N; Liu X; Wang T; Li W; Shen Y; Wang H; Qian Z; Xu H; Zhao C; Chen Y
EMBO Mol Med; 2019 Jun; 11(6):. PubMed ID: 31036704
[TBL] [Abstract][Full Text] [Related]
18. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.
Hu K; Li K; Lv J; Feng J; Chen J; Wu H; Cheng F; Jiang W; Wang J; Pei H; Chiao PJ; Cai Z; Chen Y; Liu M; Pang X
J Clin Invest; 2020 Apr; 130(4):1752-1766. PubMed ID: 31874110
[TBL] [Abstract][Full Text] [Related]
19. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
Ambrogio C; Köhler J; Zhou ZW; Wang H; Paranal R; Li J; Capelletti M; Caffarra C; Li S; Lv Q; Gondi S; Hunter JC; Lu J; Chiarle R; Santamaría D; Westover KD; Jänne PA
Cell; 2018 Feb; 172(4):857-868.e15. PubMed ID: 29336889
[TBL] [Abstract][Full Text] [Related]
20. Critical requirement of SOS1 for tumor development and microenvironment modulation in KRAS
Baltanás FC; García-Navas R; Rodríguez-Ramos P; Calzada N; Cuesta C; Borrajo J; Fuentes-Mateos R; Olarte-San Juan A; Vidaña N; Castellano E; Santos E
Nat Commun; 2023 Sep; 14(1):5856. PubMed ID: 37730692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
